2020
DOI: 10.1515/biol-2020-0078
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic effects of coronary granulocyte colony-stimulating factor on rats with chronic ischemic heart disease

Abstract: BackgroundThe aim of this study was to evaluate the therapeutic effects of coronary granulocyte colony-stimulating factor (G-CSF) on rats with chronic ischemic heart disease (CIHD).MethodsThirty healthy rats were randomly divided into control, subcutaneous and intracoronary G-CSF injection groups (n = 10) after the CIHD model was established. Left ventricular ejection fraction (LVEF), myocardial injury area, myocardial perfusion area and viable myocardium were observed by coronary angiography, dual-isotopic my… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 24 publications
(13 reference statements)
0
1
0
Order By: Relevance
“…GCSF treatment increased collateral flow and reduced infarct volume in experimental brain and myocardial ischemia models [ 16 , 17 , 18 , 19 , 20 ]. A recent preclinical study also showed that subcutaneous and intracoronary GCSF treatment improved the severity of distal stenoses and decreased the infarct size and also ameliorated ventricular remodeling and function due to pro-angiogenic and anti-apoptotic actions [ 21 ]. In a randomized study of patients with stable coronary artery disease, the pegylated GCSF analogue pegfilgrastim improved collateral function and anginal symptomatology compared to a placebo [ 22 ].…”
Section: Introductionmentioning
confidence: 99%
“…GCSF treatment increased collateral flow and reduced infarct volume in experimental brain and myocardial ischemia models [ 16 , 17 , 18 , 19 , 20 ]. A recent preclinical study also showed that subcutaneous and intracoronary GCSF treatment improved the severity of distal stenoses and decreased the infarct size and also ameliorated ventricular remodeling and function due to pro-angiogenic and anti-apoptotic actions [ 21 ]. In a randomized study of patients with stable coronary artery disease, the pegylated GCSF analogue pegfilgrastim improved collateral function and anginal symptomatology compared to a placebo [ 22 ].…”
Section: Introductionmentioning
confidence: 99%